Cargando…
Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
BACKGROUND: Troglostrongylus brevior, a lungworm usually affecting wild felids, has been recently recorded in a number of cases in domestic cats, mainly in Mediterranean areas. Although feline troglostrongylosis is a severe and life-threatening disease, especially in young cats, treatment options ar...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417080/ https://www.ncbi.nlm.nih.gov/pubmed/30867041 http://dx.doi.org/10.1186/s13071-019-3361-7 |
_version_ | 1783403494446727168 |
---|---|
author | Traversa, Donato Veronesi, Fabrizia Danesi, Patrizia Morelli, Simone Crisi, Paolo E. Morganti, Giulia Iorio, Raffaella Pampurini, Fabrizio Schaper, Roland Santoro, Azzurra Paoletti, Barbara Di Cesare, Angela |
author_facet | Traversa, Donato Veronesi, Fabrizia Danesi, Patrizia Morelli, Simone Crisi, Paolo E. Morganti, Giulia Iorio, Raffaella Pampurini, Fabrizio Schaper, Roland Santoro, Azzurra Paoletti, Barbara Di Cesare, Angela |
author_sort | Traversa, Donato |
collection | PubMed |
description | BACKGROUND: Troglostrongylus brevior, a lungworm usually affecting wild felids, has been recently recorded in a number of cases in domestic cats, mainly in Mediterranean areas. Although feline troglostrongylosis is a severe and life-threatening disease, especially in young cats, treatment options are very limited. The present study evaluated the efficacy and safety of a spot-on formulation containing emodepside 2.1% and praziquantel 8.6% (Profender(®), Bayer), which is licensed for treatment of the more common cat lungworm Aelurostrongylus abstrusus, for the treatment of natural troglostrongylosis. METHODS: Sixteen cats enrolled in the study were 1:1 allocated to two groups, i.e. Group T, treated with Profender(®) spot-on on days 0 and 14 (± 2) at the recommended clinical dose, and Group C which remained untreated. After study completion, the control cats received two rescue treatments with Profender(®) on days 28 (± 2) and 42 (± 2). The primary efficacy criterion was the absence of T. brevior L1 following treatment. Other efficacy parameters were the quantitative comparison of L1 presence before (baseline) and after treatment in both groups, and the comparison of clinical signs pre- and post-treatment. RESULTS: In terms of stopping larval shedding, Profender(®) showed an efficacy of 97% and 97.5% (arithmetic and geometric means, respectively) for group T, 97.1% and 98.5% for group C after one administration, and 100% for both groups after two doses. Overall, 12 cats showed clinical signs related to T. brevior. Specifically, 9 were clinically affected before treatment while clinical signs appeared after the first treatment in 3 cats. At the end of the study, all symptomatic cats fully recovered with the exception of 3 cats that showed clinical signs similar to those observed at the pre-treatment examination at the end of the study. CONCLUSIONS: This study shows that Profender(®) is effective against T. brevior. |
format | Online Article Text |
id | pubmed-6417080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64170802019-03-25 Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis Traversa, Donato Veronesi, Fabrizia Danesi, Patrizia Morelli, Simone Crisi, Paolo E. Morganti, Giulia Iorio, Raffaella Pampurini, Fabrizio Schaper, Roland Santoro, Azzurra Paoletti, Barbara Di Cesare, Angela Parasit Vectors Research BACKGROUND: Troglostrongylus brevior, a lungworm usually affecting wild felids, has been recently recorded in a number of cases in domestic cats, mainly in Mediterranean areas. Although feline troglostrongylosis is a severe and life-threatening disease, especially in young cats, treatment options are very limited. The present study evaluated the efficacy and safety of a spot-on formulation containing emodepside 2.1% and praziquantel 8.6% (Profender(®), Bayer), which is licensed for treatment of the more common cat lungworm Aelurostrongylus abstrusus, for the treatment of natural troglostrongylosis. METHODS: Sixteen cats enrolled in the study were 1:1 allocated to two groups, i.e. Group T, treated with Profender(®) spot-on on days 0 and 14 (± 2) at the recommended clinical dose, and Group C which remained untreated. After study completion, the control cats received two rescue treatments with Profender(®) on days 28 (± 2) and 42 (± 2). The primary efficacy criterion was the absence of T. brevior L1 following treatment. Other efficacy parameters were the quantitative comparison of L1 presence before (baseline) and after treatment in both groups, and the comparison of clinical signs pre- and post-treatment. RESULTS: In terms of stopping larval shedding, Profender(®) showed an efficacy of 97% and 97.5% (arithmetic and geometric means, respectively) for group T, 97.1% and 98.5% for group C after one administration, and 100% for both groups after two doses. Overall, 12 cats showed clinical signs related to T. brevior. Specifically, 9 were clinically affected before treatment while clinical signs appeared after the first treatment in 3 cats. At the end of the study, all symptomatic cats fully recovered with the exception of 3 cats that showed clinical signs similar to those observed at the pre-treatment examination at the end of the study. CONCLUSIONS: This study shows that Profender(®) is effective against T. brevior. BioMed Central 2019-03-12 /pmc/articles/PMC6417080/ /pubmed/30867041 http://dx.doi.org/10.1186/s13071-019-3361-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Traversa, Donato Veronesi, Fabrizia Danesi, Patrizia Morelli, Simone Crisi, Paolo E. Morganti, Giulia Iorio, Raffaella Pampurini, Fabrizio Schaper, Roland Santoro, Azzurra Paoletti, Barbara Di Cesare, Angela Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
title | Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
title_full | Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
title_fullStr | Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
title_full_unstemmed | Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
title_short | Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
title_sort | pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417080/ https://www.ncbi.nlm.nih.gov/pubmed/30867041 http://dx.doi.org/10.1186/s13071-019-3361-7 |
work_keys_str_mv | AT traversadonato pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT veronesifabrizia pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT danesipatrizia pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT morellisimone pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT crisipaoloe pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT morgantigiulia pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT iorioraffaella pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT pampurinifabrizio pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT schaperroland pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT santoroazzurra pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT paolettibarbara pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis AT dicesareangela pilotstudyevaluatingtheefficacyofatopicalformulationcontainingemodepsideandpraziquantelinthetreatmentofnaturalfelinetroglostrongylosis |